Gainers
- Salarius Pharmaceuticals SLRX shares moved upwards by 17.3% to $4.2 during Thursday's after-market session. Today's trading volume for this security ended up closing at 285.6K shares, which is 424.2 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $9.5 million.
- Midatech Pharma MTP stock moved upwards by 17.29% to $0.78. The market value of their outstanding shares is at $3.3 million.
- Nymox Pharmaceutical NYMX stock moved upwards by 11.72% to $0.53. The market value of their outstanding shares is at $47.9 million.
- Rubius Therapeutics RUBY stock moved upwards by 11.15% to $0.26. The market value of their outstanding shares is at $23.1 million.
- Ontrak OTRK shares increased by 10.82% to $1.34. Today's trading volume for this security ended up closing at 1.6 million shares, which is 51.7 percent of its average volume over the last 100 days. The company's market cap stands at $36.2 million.
- Sientra SIEN shares moved upwards by 8.07% to $0.23. The company's market cap stands at $23.1 million.
Losers
- Kala Pharmaceuticals KALA shares decreased by 10.3% to $15.9 during Thursday's after-market session. The company's market cap stands at $25.3 million.
- AnPac Bio-Medical Science ANPC shares fell 7.67% to $9.51. The market value of their outstanding shares is at $387.8 million.
- Fresh Tracks Therapeutics FRTX shares decreased by 6.89% to $2.03. The market value of their outstanding shares is at $6.1 million.
- Infinity Pharmaceuticals INFI stock fell 6.0% to $0.65. The market value of their outstanding shares is at $58.1 million.
- Synlogic SYBX shares fell 5.01% to $0.95. Trading volume for this security closed at 933.6K, accounting for 579.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $66.9 million.
- Aprea Therapeutics APRE shares decreased by 5.0% to $0.46. The company's market cap stands at $24.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in